Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

被引：0
|
作者：
Moreno, Amy [1 ]
Akcakanat, Argun [1 ]
Munsell, Mark F. [1 ]
Soni, Alpana [1 ]
Yao, James [1 ]
Meric-Bernstam, Funda [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3583S / 3583S
页数：1
相关论文
共 50 条
  • [31] Development of a method for preparing octreotide derivative for diagnosis of neuroendocrine tumors
    Larkina, M. S.
    Podrezova, E., V
    Bragina, O. D.
    Tagirova, E. A.
    Chernov, V., I
    Yusubov, M. S.
    Nesterov, E. A.
    Skuridin, V. S.
    Krivoshchekov, S., V
    Yanovskaya, E. A.
    Gurto, R., V
    Belousov, M., V
    BYULLETEN SIBIRSKOY MEDITSINY, 2019, 18 (03): : 72 - 80
  • [32] Octreotide use in patients with metastatic pancreatic neuroendocrine tumors.
    Cheema, A.
    Weber, J.
    Kvols, L. K.
    Strosberg, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Alternating lanreotide and octreotide in the treatment of metastatic neuroendocrine tumors (NETs)
    Koussis, H.
    Scola, A.
    Cirillo, F.
    Basso, U.
    Ziampiri, S.
    Casara, D.
    Pelizzo, M. R.
    Rebustello, F.
    Behboo, R.
    Jirillo, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy
    Geoerger, B
    Kerr, K
    Tang, CB
    Fung, KM
    Powell, B
    Sutton, LN
    Phillips, PC
    Janss, AJ
    CANCER RESEARCH, 2001, 61 (04) : 1527 - 1532
  • [35] Somatostatin Receptor Subtypes, Octreotide Scintigraphy, and Clinical Response to Octreotide Treatment in Patients with Neuroendocrine Tumors
    Lars Kölby
    Bo Wängberg
    Håkan Ahlman
    Lars-Erik Tisell
    Martha Fjälling
    Eva Forssell-Aronsson
    Ola Nilsson
    World Journal of Surgery, 1998, 22 : 679 - 683
  • [36] Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors
    Kölby, L
    Wängberg, B
    Ahlman, H
    Tisell, LE
    Fjälling, M
    Forssell-Aronsson, E
    Nilsson, O
    WORLD JOURNAL OF SURGERY, 1998, 22 (07) : 679 - 683
  • [37] Potent antitumor activity of CHS 828 on xenografted human neuroendocrine tumors in nude mice
    Johanson, V
    Arvidsson, Y
    Kölby, L
    Bernhardt, P
    Swärd, C
    Nilsson, O
    Ahlman, H
    NEUROENDOCRINOLOGY, 2006, 83 (01) : 58 - 58
  • [38] Novel Agents in Gastroenteropancreatic Neuroendocrine Tumors
    Stevenson, Ryan
    Libutti, Steven K.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2013, 14 (02): : 152 - 154
  • [39] 111In-octreotide bone metastases detection in carcinoid tumors and pancreatic neuroendocrine tumors
    Banzo, J
    Abós, MD
    Prats, E
    Razola, P
    García, S
    Gomollón, F
    García, F
    Freile, E
    Escalera, T
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1177 - 1177
  • [40] Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model
    Ciomei, M
    Croci, V
    Ciavolella, A
    Ballinar, D
    Pesenti, E
    CLINICAL CANCER RESEARCH, 2006, 12 (09) : 2856 - 2861
12345